The interplay between environmental and genetic factors in Parkinson's disease susceptibility: The evidence for pesticides

Toxicology

Volumn 307, Issue , 2013, Pages 17-23

  Dardiotis, Efthimios ^a   Xiromerisiou, Georgia ^a   Hadjichristodoulou, Christos ^a   Tsatsakis, Aristidis M ^b   Wilks, Martin F ^c   Hadjigeorgiou, Georgios M ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Gene environmental interaction; Genetic association studies; Parkinson's disease; Pesticides

Indexed keywords

ABC TRANSPORTER; ALPHA SYNUCLEIN; ARYLDIALKYLPHOSPHATASE 1; ATP BINDING CASSETTE SUBFAMILY B MEMBER 1; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOCHROME P450 1B1; CYTOCHROME P450 2D6; DOPAMINE TRANSPORTER; GLUTATHIONE TRANSFERASE; HEME OXYGENASE 1; LEUCINE RICH REPEAT KINASE 2; MANGANESE SUPEROXIDE DISMUTASE; NITRIC OXIDE SYNTHASE; OXIDOREDUCTASE; PESTICIDE; PHOSPHOTRANSFERASE; PTEN INDUCED PUTATIVE KINASE 1; QUINONE OXIDOREDUCTASE 1; UNCLASSIFIED DRUG; ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN;

ARTICLE; CAUCASIAN; DNA POLYMORPHISM; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HEREDITY; HETEROZYGOTE; HOMOZYGOTE; METABOLIC RATE; NERVE DEGENERATION; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN STABILITY; RNA SPLICING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MITOCHONDRION; REVIEW; RISK FACTOR;

ARYLDIALKYLPHOSPHATASE; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; PESTICIDES; RISK FACTORS;

MLCS; MLOWN;

EID: 84880062073     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2012.12.016     Document Type: Article

References (62)

1. Adler V., Yin Z., Fuchs S.Y., Benezra M., Rosario L., Tew K.D., Pincus M.R., Sardana M., Henderson C.J., Wolf C.R., Davis R.J., Ronai Z. Regulation of JNK signaling by GSTp. Embo J. 1999, 18:1321-1334.
2. Androutsopoulos V.P., Kanavouras K., Tsatsakis A.M. Role of paraoxonase 1 (PON1) in organophosphate metabolism: implications in neurodegenerative diseases. Toxicol. Appl. Pharmacol. 2011, 256:418-424.
3. Ascherio A., Chen H., Weisskopf M.G., O'Reilly E., McCullough M.L., Calle E.E., Schwarzschild M.A., Thun M.J. Pesticide exposure and risk for Parkinson's disease. Ann. Neurol. 2006, 60:197-203.
4. Behari M., Srivastava A.K., Das R.R., Pandey R.M. Risk factors of Parkinson's disease in Indian patients. J. Neurol. Sci. 2001, 190:49-55.
5. Belin A.C., Ran C., Anvret A., Paddock S., Westerlund M., Hakansson A., Nissbrandt H., Soderkvist P., Dizdar N., Ahmadi A., Anvret M., Willows T., Sydow O., Galter D. Association of a protective paraoxonase 1 (PON1) polymorphism in Parkinson's disease. Neurosci. Lett. 2012, 522:30-35.
6. Brighina L., Frigerio R., Schneider N.K., Lesnick T.G., de Andrade M., Cunningham J.M., Farrer M.J., Lincoln S.J., Checkoway H., Rocca W.A., Maraganore D.M. Alpha-synuclein, pesticides, and Parkinson disease: a case-control study. Neurology 2008, 70:1461-1469.
7. Brown T.P., Rumsby P.C., Capleton A.C., Rushton L., Levy L.S. Pesticides and Parkinson's disease - is there a link?. Environ. Health Perspect. 2006, 114:156-164.
8. Burbulla L.F., Kruger R. Converging environmental and genetic pathways in the pathogenesis of Parkinson's disease. J. Neurol. Sci. 2011, 306:1-8.
9. Chan D.K., Woo J., Ho S.C., Pang C.P., Law L.K., Ng P.W., Hung W.T., Kwok T., Hui E., Orr K., Leung M.F., Kay R. Genetic and environmental risk factors for Parkinson's disease in a Chinese population. J. Neurol. Neurosurg. Psychiatr. 1998, 65:781-784.
10. Costa L.G., Giordano G., Cole T.B., Marsillach J., Furlong C.E. Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology 2012.
11. Deng Y., Newman B., Dunne M.P., Silburn P.A., Mellick G.D. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. Ann. Neurol. 2004, 55:897.
12. Dick F.D., De Palma G., Ahmadi A., Osborne A., Scott N.W., Prescott G.J., Bennett J., Semple S., Dick S., Mozzoni P., Haites N., Wettinger S.B., Mutti A., Otelea M., Seaton A., Soderkvist P., Felice A. Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study. Occup. Environ. Med. 2007, 64:673-680.
13. Drozdzik M., Bialecka M., Mysliwiec K., Honczarenko K., Stankiewicz J., Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003, 13:259-263.
14. Dutheil F., Beaune P., Tzourio C., Loriot M.A., Elbaz A. Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. Arch. Neurol. 2010, 67:739-745.
15. Edwards R.H. Neural degeneration and the transport of neurotransmitters. Ann. Neurol. 1993, 34:638-645.
16. Elbaz A., Levecque C., Clavel J., Vidal J.S., Richard F., Amouyel P., Alperovitch A., Chartier-Harlin M.C., Tzourio C. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Ann. Neurol. 2004, 55:430-434.
17. Fernandez-Gonzalez A., Perez-Otano I., Morgan J.I. MPTP selectively induces haem oxygenase-1 expression in striatal astrocytes. Eur. J. Neurosci. 2000, 12:1573-1583.
18. Fong C.S., Cheng C.W., Wu R.M. Pesticides exposure and genetic polymorphism of paraoxonase in the susceptibility of Parkinson's disease. Acta Neurol. Taiwan 2005, 14:55-60.
19. Fong C.S., Wu R.M., Shieh J.C., Chao Y.T., Fu Y.P., Kuao C.L., Cheng C.W. Pesticide exposure on southwestern Taiwanese with MnSOD and NQO1 polymorphisms is associated with increased risk of Parkinson's disease. Clin. Chim. Acta 2007, 378:136-141.
20. Frigerio R., Sanft K.R., Grossardt B.R., Peterson B.J., Elbaz A., Bower J.H., Ahlskog J.E., de Andrade M., Maraganore D.M., Rocca W.A. Chemical exposures and Parkinson's disease: a population-based case-control study. Mov. Disord. 2006, 21:1688-1692.
21. Gao H.M., Hong J.S. Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Prog. Neurobiol. 2011, 94:1-19.
22. Garin M.C., James R.W., Dussoix P., Blanche H., Passa P., Froguel P., Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 1997, 99:62-66.
23. Gatto N.M., Rhodes S.L., Manthripragada A.D., Bronstein J., Cockburn M., Farrer M., Ritz B. Alpha-synuclein gene may interact with environmental factors in increasing risk of Parkinson's disease. Neuroepidemiology 2010, 35:191-195.
24. Godeiro C., Aguiar P.M., Felicio A.C., Barsottini O.G., Silva S.M., Borges V., Andrade L.A., Ferraz H.B. PINK1 polymorphism IVS1-7 A-->G, exposure to environmental risk factors and anticipation of disease onset in Brazilian patients with early-onset Parkinson's Disease. Neurosci. Lett. 2010, 469:155-158.
25. Gough A.C., Miles J.S., Spurr N.K., Moss J.E., Gaedigk A., Eichelbaum M., Wolf C.R. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990, 347:773-776.
26. Grasbon-Frodl E.M., Kosel S., Riess O., Muller U., Mehraein P., Graeber M.B. Analysis of mitochondrial targeting sequence and coding region polymorphisms of the manganese superoxide dismutase gene in German Parkinson disease patients. Biochem. Biophys. Res. Commun. 1999, 255:749-752.
27. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., van der Brug M.P., Beilina A., Blackinton J., Thomas K.J., Ahmad R., Miller D.W., Kesavapany S., Singleton A., Lees A., Harvey R.J., Harvey K., Cookson M.R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 2006, 23:329-341.
28. Hadjigeorgiou G.M., Malizos K., Dardiotis E., Aggelakis K., Dardioti M., Zibis A., Dimitroulias A., Scarmeas N., Tsezou A., Karantanas A. Paraoxonase 1 gene polymorphisms in patients with osteonecrosis of the femoral head with and without cerebral white matter lesions. J. Orthop. Res. 2007, 25:1087-1093.
29. Hancock D.B., Martin E.R., Vance J.M., Scott W.K. Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease. Neurogenetics 2008, 9:249-262.
30. Hayes J.D., Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 1995, 30:445-600.
31. Infante J., Sierra M., Sanchez-Juan P., Garcia-Gorostiaga I., Gonzalez-Aramburu I., Fernandez-Viadero C., Berciano J., Combarros O. Interaction between heme oxygenase-1 genotypes and exposure to pesticides in Parkinson's disease. Mov. Disord. 2011, 26:916-917.
32. Kanavouras K., Tzatzarakis M.N., Mastorodemos V., Plaitakis A., Tsatsakis A.M. A case report of motor neuron disease in a patient showing significant level of DDTs, HCHs and organophosphate metabolites in hair as well as levels of hexane and toluene in blood. Toxicol. Appl. Pharmacol. 2011, 256:399-404.
33. Kelada S.N., Checkoway H., Kardia S.L., Carlson C.S., Costa-Mallen P., Eaton D.L., Firestone J., Powers K.M., Swanson P.D., Franklin G.M., Longstreth W.T., Weller T.S., Afsharinejad Z., Costa L.G. 5' and 3' region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study. Hum. Mol. Genet. 2006, 15:3055-3062.
34. Kiyohara C., Miyake Y., Koyanagi M., Fujimoto T., Shirasawa S., Tanaka K., Fukushima W., Sasaki S., Tsuboi Y., Yamada T., Oeda T., Miki T., Kawamura N., Sakae N., Fukuyama H., Hirota Y., Nagai M. GST polymorphisms, interaction with smoking and pesticide use, and risk for Parkinson's disease in a Japanese population. Parkinsonism Relat. Disord. 2010, 16:447-452.
35. Kokouva M., Koureas M., Dardiotis E., Almpanidou P., Kalogeraki A., Kyriakou D., Hadjigeorgiou G.M., Hadjichristodoulou C. Relationship between the paraoxonase 1 (PON1) M55L and Q192R polymorphisms and lymphohaematopoietic cancers in a Greek agricultural population. Toxicology 2012.
36. Kuehl B.L., Paterson J.W., Peacock J.W., Paterson M.C., Rauth A.M. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br. J. Cancer 1995, 72:555-561.
37. Leppa S., Bohmann D. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 1999, 18:6158-6162.
38. Leviev I., Deakin S., James R.W. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J. Lipid Res. 2001, 42:528-535.
39. Leviev I., James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 2000, 20:516-521.
40. Li A.A., Mink P.J., McIntosh L.J., Teta M.J., Finley B. Evaluation of epidemiologic and animal data associating pesticides with Parkinson's disease. J. Occup. Environ. Med. 2005, 47:1059-1087.
41. Li W.F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Tward A., Lusis A.J., Furlong C.E. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000, 10:767-779.
42. Lill C.M., Roehr J.T., McQueen M.B., Kavvoura F.K., Bagade S., Schjeide B.M., Schjeide L.M., Meissner E., Zauft U., Allen N.C., Liu T., Schilling M., Anderson K.J., Beecham G., Berg D., Biernacka J.M., Brice A., DeStefano A.L., Do C.B., Eriksson N., Factor S.A., Farrer M.J., Foroud T., Gasser T., Hamza T., Hardy J.A., Heutink P., Hill-Burns E.M., Klein C., Latourelle J.C., Maraganore D.M., Martin E.R., Martinez M., Myers R.H., Nalls M.A., Pankratz N., Payami H., Satake W., Scott W.K., Sharma M., Singleton A.B., Stefansson K., Toda T., Tung J.Y., Vance J., Wood N.W., Zabetian C.P., Young P., Tanzi R.E., Khoury M.J., Zipp F., Lehrach H., Ioannidis J.P., Bertram L. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet. 2012, 8:e1002548.
43. Lin C.H., Wu R.M., Tai C.H., Chen M.L., Hu F.C. Lrrk2 S1647T and BDNF V66M interact with environmental factors to increase risk of Parkinson's disease. Parkinsonism Relat. Disord. 2011, 17:84-88.
44. Litwack G., Ketterer B., Arias I.M. Ligandin: a hepatic protein which binds steroids, bilirubin, carcinogens and a number of exogenous organic anions. Nature 1971, 234:466-467.
45. Manthripragada A.D., Costello S., Cockburn M.G., Bronstein J.M., Ritz B. Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease. Epidemiology 2010, 21:87-94.
46. Menegon A., Board P.G., Blackburn A.C., Mellick G.D., Le Couteur D.G. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 1998, 352:1344-1346.
47. Neafsey P., Ginsberg G., Hattis D., Sonawane B. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J. Toxicol. Environ. Health B Crit. Rev. 2009, 12:334-361.
48. Nuti A., Ceravolo R., Dell'Agnello G., Gambaccini G., Bellini G., Kiferle L., Rossi C., Logi C., Bonuccelli U. Environmental factors and Parkinson's disease: a case-control study in the Tuscany region of Italy. Parkinsonism Relat. Disord. 2004, 10:481-485.
49. O'Leary K.A., Edwards R.J., Town M.M., Boobis A.R. Genetic and other sources of variation in the activity of serum paraoxonase/diazoxonase in humans: consequences for risk from exposure to diazinon. Pharmacogenet. Genomics 2005, 15:51-60.
50. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
51. Priyadarshi A., Khuder S.A., Schaub E.A., Shrivastava S. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 2000, 21:435-440.
52. Richardson J.R., Quan Y., Sherer T.B., Greenamyre J.T., Miller G.W. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol. Sci. 2005, 88:193-201.
53. Ritz B.R., Manthripragada A.D., Costello S., Lincoln S.J., Farrer M.J., Cockburn M., Bronstein J. Dopamine transporter genetic variants and pesticides in Parkinson's disease. Environ. Health Perspect. 2009, 117:964-969.
54. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., Riele H.P., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491-502.
55. Uversky V.N., Li J., Fink A.L. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett. 2001, 500:105-108.
56. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160.
57. Wilk J.B., Tobin J.E., Suchowersky O., Shill H.A., Klein C., Wooten G.F., Lew M.F., Mark M.H., Guttman M., Watts R.L., Singer C., Growdon J.H., Latourelle J.C., Saint-Hilaire M.H., DeStefano A.L., Prakash R., Williamson S., Berg C.J., Sun M., Goldwurm S., Pezzoli G., Racette B.A., Perlmutter J.S., Parsian A., Baker K.B., Giroux M.L., Litvan I., Pramstaller P.P., Nicholson G., Burn D.J., Chinnery P.F., Vieregge P., Slevin J.T., Cambi F., MacDonald M.E., Gusella J.F., Myers R.H., Golbe L.I. Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD study. Neurology 2006, 67:2206-2210.
58. Wirdefeldt K., Adami H.O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 2011, 26(Suppl. 1):S1-S58.
59. Xiromerisiou G., Dardiotis E., Tsimourtou V., Kountra P.M., Paterakis K.N., Kapsalaki E.Z., Fountas K.N., Hadjigeorgiou G.M. Genetic basis of Parkinson disease. Neurosurg. Focus 2010, 28:E7.
60. Zhou S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin. Pharmacokinet. 2009, 48:689-723.
61. Zintzaras E., Hadjigeorgiou G.M. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. J. Hum. Genet. 2004, 49:474-481.
62. Zschiedrich K., Konig I.R., Bruggemann N., Kock N., Kasten M., Leenders K.L., Kostic V., Vieregge P., Ziegler A., Klein C., Lohmann K. MDR1 variants and risk of Parkinson disease. Association with pesticide exposure?. J. Neurol. 2009, 256:115-120.